Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant –
- Omidubicel has Orphan Drug Designation and Breakthrough Therapy Designation -
https://finance.yahoo.com/news/gamida-cell-completes-rolling-biologics-110000831.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.